Research Article
Overexpression of miR-375 Protects Cardiomyocyte Injury following Hypoxic-Reoxygenation Injury
Table 1
Clinical parameters of the study subjects.
| | Clinical parameters | STEMI () | NSTEMI () | Healthy subjects () | 1 | 2 | 3 |
| | Sex (male/female) | 53/42 | 39/36 | 53/42 | 1.000 | 0.645 | 1.000 | | Age (years) | | | | 0.525 | 0.456 | 0.889 | | Tobacco | 73% (65) | 72% (54) | 58% (52) | 0.060 | 0.073 | 0.556 | | Hypertension | 78% (70) | 76% (57) | 0 | ≠ | ≠ | 0.854 | | Hypercholesterolemia | 80% (72) | 77% (58) | 0 | ≠ | ≠ | 0.706 | | Diabetes mellitus | 32% (29) | 31% (23) | 0 | ≠ | ≠ | 0.868 | | Body mass index (kg/m2) | | | | 0.000 | 0.000 | 0.116 | | Previous MI | 11% (10) | 6% (5) | 0 | ≠ | ≠ | 0.419 | | Previous CABG | 3% (3) | 2% (2) | 0 | ≠ | ≠ | 1.000 | | Previous PTCA | 6 | 4 | 0 | | | 0.729 | | Glucose (mmol/L) | | | | 0.000 | 0.000 | 0.624 | | High-sensitivity C-reactive protein (mg/L) | | | | 0.000 | 0.000 | 0.006 | | LDH (U/L) | | | | 0.000 | 0.000 | 0.000 | | CK-MB (U/L) | | | | 0.000 | 0.000 | 0.000 | | cTnT (μg/L) | | | 0 | ≠ | ≠ | 0.000 | | Aspirin use | 63% (57) | 56% (42) | 0 | ≠ | ≠ | 0.344 | | Clopidogrel use | 46% (41) | 42% (32) | 0 | ≠ | ≠ | 0.754 | | Beta blocker use | 84% (76) | 84% (63) | 0 | ≠ | ≠ | 1.000 | | Nitrates use | 85% (77) | 81% (61) | 0 | ≠ | ≠ | 0.529 | | Angiotensin-converting-enzyme inhibitor drugs use | 37% (33) | 36% (27) | 0 | ≠ | ≠ | 1.000 | | Angiotensin receptor blocker use | 14% (13) | 12% (8) | 0 | ≠ | ≠ | 0.819 | | Calcium channel blocker use | 13% (12) | 11% (8) | 0 | ≠ | ≠ | 0.640 | | Lipid-lowering drugs | 72% | 72% | 0 | ≠ | ≠ | 1.000 |
|
|
CABG: coronary artery bypass graft; PTCA: percutaneous transluminal coronary angioplasty; LDH: lactate dehydrogenase; CK-MB: creatine kinase-MB; cTnT: cardiac troponin T. 1 (controls and STEMI), 2 (controls and NSTEMI), 3 (STEMI and NSTEMI). |
